Introduction {#S1}
============

Nowadays radiotherapy (RT) alone or most frequently combined with chemotherapy (RCT) is considered a valid alternative treatment to surgery for patients affected by head and neck cancer (HNC) in order to preserve the deglutition organ [@R01] [@R02]. Historically, conventional RT has been burdened by severe and potentially \"life threatening\" toxicity that limited the delivery of high tumour radiation dose and in most cases affected the final treatment result [@R03]^-^[@R06]. In this regard radiation-induced dysphagia, as a final multifactorial side effect often requiring enteral nutrition, represents a real \"Achille\'s heel\" that occurs in more than 50% of patients and can lead to a malnutritional status and an increased risk of aspiration pneumonia [@R07]^-^[@R09]. The 1-and 2-year rates of percutaneous endoscopic gastrostomy (PEG) tube dependence is reported, respectively, in 24% and 14%, whereas clinical aspiration pneumonia is reported in 3% of cases [@R10].

On the contrary, an organ preservation strategy should provide both the highest tumour control probability (TCP) and the minimum function impairment with the subsequent maximum therapeutic index gain.

In fact, reducing deglutition disorders related-symptoms (e.g., oropharyngeal pain, dry mouth, food stuck in the throat and choking) and deglutition disorder related-complications (pulmonary complications) can result both in a significant improvement of patient quality of life (QoL) together with a reduction in hospitalisation costs [@R11]^-^[@R13].

In the last few decades, the advancement of treatment technologies, such as intensity and modulated radiotherapy (IMRT), has shown promising results in terms of better TCP as well as a reduction of toxicity through the sparing of swallowing organs at risk (SWOARs) [@R14] [@R15].

Hence, several studies have investigated the impact of RT using IMRT on the deglutition function but are mostly retrospective, addressed to an heterogeneous set of patients and lacking preatreatment swallowing evaluation [@R16]^-^[@R20].

Moreover, in most cases dysphagia was defined using a surrogate clinical endpoint, such as percutaneous tube dependence (PEG) time, aspiration pneumonia or pharingoesophageal strictures. Differently, the assessment of deglutition function typically includes both clinical and instrumental evaluation [@R11].

Although several objective patient-reported instruments, such as Radiation Therapy Oncology Group (RTOG)/ European Organization for Research and Treatment of Cancer (EORTC) criteria, the Subjective Objective Management Analytic (SOMA) scale and the Common Terminology Criteria for Adverse Events (CTCAE) are available [@R20]^-^[@R23], they are variable and have been shown to underestimate deglutition impairment compared with objective instrumental assessment [@R24]. Indeed, a clear and uniform consensus of objective instrumental deglutition assessment has yet not been clearly defined.

Videofluoroscopy (VFS) and fiberoptic endoscopic evaluation of swallowing (FEES) are considered the gold standards for dysphagia assessment, whereas oropharyngealossophageal scintigraphy (OPES) is considered optional combined with FEES and VFS [@R25].

Thus, due to the reliability and validity of instrumental assessment tools, the use of all available complementary procedures is suggested by the current literature to properly evaluate swallowing function [@R25] [@R26].

We therefore initiated a prospective longitudinal study to assess the impact of RT on swallowing function in a homogeneous subset of HNC patients who were candidates for radio or chemoradiotherapy as a radical curative treatment.

The primary endpoint was to evaluate dysphagia parameter changes using pre and post-treatment objective instrumental assessment after IMRT aimed to reduce the radiation dose to the SWOARs.

In this study, we report our preliminary results focusing on acute dysphagia (1 month after treatment), not previously investigated, in order to assess the risk of severe complications during or soon after RT or RCT.

Materials and methods {#S2}
=====================

Patient characteristics {#S2a}
-----------------------

This is an ongoing prospective study carried out by the collaboration of the Department of Radiation Oncology, the Department of Radiology and the Otorhinolaringology and Speech Language Pathologist Unit. The study was approved by the Institutional Review Board of the University of Pisa; all patients signed a study-specific informed consent form.

The eligibility criteria included all patients affected by nasopharynx and oropharynx cancer (Stage II-IVA), with histological proven diagnosis of undifferentiated nasopharyngeal- type carcinoma or squamous cell carcinoma, Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2 and age \< 80 years old.

Exclusion criteria were the following: a different site from nasopharynx or oropharynx, a different histology from undifferentiated nasopharyngeal type or squamous cell carcinoma, ECOG Status ≥ 3, Stage IVB and C, prior induction chemotherapy or prior HN treatment (surgery and/or RT), diagnosis of concomitant comorbidity which might compromise basic deglutition function (demyelinating or degenerative diseases and connective tissue diseases) and age \> 80 years.

Radiotherapy {#S2b}
------------

All patients required bilateral neck irradiation and underwent whole-neck-field IMRT; the anterior low neck field abutting the upper IMRT region was not used in any patient.

The clinical target volumes (CTVs) were directly delineated by the radiation oncologist according to the guidelines of the Italian Association of Radiation Oncology- Head and Neck Working Group [@R27] and the corresponding planning target volumes (PTVs) were automatically created by uniform expansions of 0.3 cm.

According to our internal image guided radiotherapy (IGRT) protocol, patients underwent weekly cone beam CT (CBCT) set-up control and online correction to reduce systematic set-up errors.

The prescribed doses were 66 Gy at 2.2 Gy per fraction to the high risk gross volume PTV and 60-54 Gy at 2.0-1.8 Gy per fraction to the intermediate (optional) and low risk subclinical PTVs, respectively, delivered concomitantly in 30 daily fractions.

According to the recent computed tomography (CT)- based delineation guidelines by Christianen et al. [@R28], eight different SWOARs were defined in each CT slice and included in IMRT planning objective functions: superior, middle and inferior constrictor muscle (SPCM, MPCM and IPCM), supraglottic larynx (SL), glottis larynx (GL), cricopharyngeus muscle (CPM) and cervical oesophagus (CE). Thereafter, the mean dose received by each swallowing structures as well as by parotid glands and oral cavity were recorded.

In the IMRT optimisation cost function, target coverage replaced sparing of any SWOARs, parotid glands and oral cavity, but the spinal cord.

The IMRT plans set target prescription goals and spinal cord maximum dose (D~max~) as the highest priority, whereas SWOAR constraints were set as secondary.

Medical therapy, supportive care and follow-up {#S2c}
----------------------------------------------

Chemotherapy was given weekly using cisplatin 40 mg/ m[@R02] i.v. over 1 h during the 6-week RT course for a maximum of 6 cycles both for patients affected by nasopharynx or oropharynx cancer.

For oropharynx patients with severe comorbidities, cetuximab was administered as an induction dose of 400 mg[@R02] over 2 h at 1 week before the start of RT and then 250 mg[@R02] weekly over 1-hour during RT course for a maximum of 6 cycles was administered.

Patients underwent PEG positioning during or after treatment if weight loss was \> 10% (grade 2) from pretreatment status.

Acute toxicity was reported according to Common Toxicity Criteria Adverse Effects (CTCAE) version 3 [@R23], an observer-assessed validated toxicity scale scoring dysphagia between grade 1 (symptomatic but able to eat regular diet) to grade 5 (death).

Evaluation of dysphagia {#S2d}
-----------------------

### Oro-pharyngeal-oesophageal scintigraphy (OPES) {#S2da}

OPES investigation entails the acquisition of a rapid sequence of images referring to a single voluntary deglutition

which the patient performs on command. It is preferable to carry out this scintigraphic examination after the patient has been without food for at least three hours. Before starting the OPES, the patient should be made to swallow a small amount of non-radioactive water as a test; this helps to train the patients regarding the procedure, ensures patient compliance and assesses the capacity to swallow the amount of liquid foreseen for the examination (5 cc). After about five minutes, the examination begins with the patient in an orthostatic position with his/her face in an 80° oblique projection in front of a single rectangular headed large-field-of--view (LFOV) gamma camera equipped with a low energy-high resolution (LEHR) parallel hole collimator using a 140 KeV (± 10%) energy window. The patient is administered a single bolus of 5 cc of water marked with 37 MBq (1 mCi) of ^99m^Tc nanocolloid (Nanocoll-Amersham^®^, UK). Eight images per sec (0.125 sec/frame) are acquired for one min by dynamic acquisitions (with a 64 x 64 matrix and zoom at 1), including the oral region as far as the epigastric area within the imaging field. The pharyngeal region of interest (ROI ) is that between the oral cavity and the external reference corresponding to the pharyngo- oesophageal transition [@R29].

Two seconds after the start, the patient is invited to take the liquid bolus in one deglutition (OPES-L). At the end of the test, a static image lasting 60 sec is acquired, with the patient still in the same position to evaluate any possible tracheo-bronchial aspiration.

After an interval of 30 min, the procedure is repeated, but this time with a semi-solid bolus marked with 37 MBq (1 mCi) of ^99m^Tc nanocolloid (OPES-SL). The acquisitions are obtained with the same method as with the liquid bolus.

### Videofluoroscopy (VFS) {#S2db}

Digital fluoroscopy examinations were performed with a Clinodigit Compact Xframe Italray^®^ device. The digital images were acquired by filming at a frame rate of 30/sec, which was sufficient to record the swallowing act. The acquisition resolution was 30,001 x 3001 x 14 bit.

Digitalised imaging permits the creation of a PACS (Picture Archiving and Communication System), which is a computerised system where images are uploaded, together with the relative supplied by the various diagnostic tools available in the hospital, thus allowing the images to be archived and shared. Furthermore, PACS permits viewing information about any previous investigation the patient was submitted to whenever a new examination was necessary. An image was enlarged on the neck region of the patient in an orthostatic latero-lateral position, and contrast medium was administered. The contrast medium used was Prontobario HD (Bracco^®^): the packaging supplied contains 98.45 g powder for oral suspension, 340 g barium sulphate.

The powder was diluted in 65 ml of water for the liquid consistency (VFS-L) and in 30 ml of water for the semisolid bolus (VFS-SL); for each density, the patient was invited to take three 5 cc sips [@R30]^-^[@R32].

### Fibreoptic endoscopic evaluation of swallowing (FEES) {#S2dc}

FEES was performed with a flexible fibreoptic rhinopharyngolaryngoscope (Olympus ENF-P3^®^) connected to a CCD camera and colour monitor and recorded digitally on the Digital Swallowing Workstation (Kay Pentax Ltd^®^, Montvale, NJ, USA). The examination was carried out by a phoniatrician and a speech therapist and every patient was administered two or more semi-solid (viscous water) or liquid boluses (water marked with blue methylene for easy detection), swallowing 5 cc of each type of bolus [@R30]^-^[@R32].

Four different dysphagia parameters were calculated and reported at each exam both after liquid (L) and semi-liquid (SL) bolus intake. Pre-deglutition penetration, hypopharyngeal retention index (HPRI) and penetration/aspiration were reported at each exam, whereas pharyngeal transit time (PTT) and white-out phase (WOP) only at VFS/ OPES and at FEES, respectively. The evaluation of both pre-deglutition penetration and penetration/aspiration was scored 0 if it was absent and 1 if was present. The latter was defined at FEES and VFS once the bolus entered the upper airways above the vocal cords (penetration) or passed below the vocal cords into the subglottis (aspiration).

The OPES detected only the transit of bolus into the tracheobronchial tree (aspiration), also giving the possibility for semi quantitative measurement of the aspirate.

Thereafter, the penetration/aspiration was classified in 8 different scores according to the worldwide used Penetration- Aspiration Scale at VFS [@R33].

The PTT was calculated at the end of the test by evaluation of the images recorded (normal \< = 1 sec; Score 0), slightly long (≥ 1 to \< 1.5 sec; Score 1), long (≥ 1.5 to \< 2 sec; Score 2) and very long (≥ 2 sec; Score 3).

The WOP was defined as the total amount of time that the entire view screen was completely white.

The endoscopic examination was reviewed in a frameby- frame analysis (ATMOS recording system), which allowed marking the examination film at specific points using a running frame-by-frame counter with a capture film rate of 30 frames per sec.

Swallowing initiation was defined as the time from when the bolus reached the horizontal level at the tip of the epiglottis to the start of the complete \"white out.\" The HPRI was calculated as the amount of residue (pooling amount) in the hypopharynx against the Farneti pooling-score scale. Score 0 was considered normal, whereas scores 1, 2 and 3 pathological (mild, moderate and severe, respectively). Dysphagia parameters scores are shown in [Table I](#T1){ref-type="table"}.

###### 

Videofluoroscopy, fibreoptic endoscopic evaluation of swallowing and oro-pharyngeal-oesophageal scintigraphy dysphagia parameter scores.

                                                                                             Absent                                        Present   
  -------------------------------------------------------------------------------- --------- -------- ----------------- ------------------ --------- ---------
  Pre-swallowing penetration                                                                 0                                             1         
  Penetration/aspiration                                                                     0                                             1         
  PTT [^a^](#T1FN1){ref-type="table-fn"} /WOP [^b^](#T1FN2){ref-type="table-fn"}   Normal             Mild              Moderate                     Severe
  HPRI [^c^](#T1FN3){ref-type="table-fn"}                                          0                  1                 2                            3
  Videofluoroscopy                                                                 0                  1                 2                            3
  (Dyer et al. [@R34])                                                             (\< 3%)            (≥ 3 to \< 25%)   (≥ 25 to \< 55%)             (≥ 55%)
  Scintigraphy                                                                     0                  1                 2                            3
  (Fattori et al. [@R35])                                                          (\< 5%)            (≥ 5 to \< 20%)   (≥ 20 to \< 40%)             (≥ 40%)
  Fibreoptic evaluation                                                            0                  1                 2                            3
  (Farneti et al. [@R36])                                                                                                                            

PTT = Pharyngeal transit time. Values are numbers and (percentage)

WOP = White-out phase. Values are numbers and (percentage)

HPRI = Hypopharyngeal retention index. Values are numbers and (percentage)

Statistical parameter {#S2e}
---------------------

We studied three main factors: dysphagia temporal variations, baseline dysphagia and the effect of liquid-semiliquid bolus. Before testing of inferential statistics, a graphical exploration was always performed.

Dysphagia temporal variations {#S2f}
-----------------------------

To detect the significant changes in the dysphagia scores, measured at time zero and after 1 month, we used the Wilcoxon test (for continuous variables) and the McNemar test (for dichotomous variables). For continuous variables, worsening score was considered as the transition from a lower to a higher score (e.g. from 0 to 1 or from 1 to 2).

Evaluation baseline dysphagia {#S2g}
-----------------------------

To evaluate the association among the primary tumour site (nasopharynx, oropharynx), T stage and N stage with the baseline dysphagia score (low, medium-high) measured by several instrumental analysis, two-tailed chi-square test and Fisher\'s exact test were used.

Effect of liquid-semiliquid bolus {#S2h}
---------------------------------

To evaluate the correlation between deglutition worsening scores (from before to 1 month after treatment) for different bolus consistencies (L and SL) at the same exam (FEES/VFS/OPES), we used a non-parametric correlation analysis.

All statistical analyses, including those on the radiation doses received by the SWOARs (box-plots) and the variations between scores changes (bar graph), were performed using SPSS 21.

Results {#S3}
=======

Between June 2012 and December 2013, 20 patients with nasopharynx (n = 6) or oropharynx (n = 14) cancer were enrolled. The summaries of baseline patient and tumour characteristics are detailed in [Table II](#T2){ref-type="table"}. Average ± standard deviation mean doses to the SPCM, MPCM, IPCM, BOT, SL, GL, CPM and CE were 56.7 ± 13.7Gy, 53.4Gy ± 8.2Gy, 44.7 ± 11Gy, 55.7 ± 8.7Gy, 47.5 ± 11.2 Gy, 41.5 ± 11.3Gy, 41.7 ± 12.9Gy and EC 27.8 ± 10.3 Gy, respectively ([Fig. 1](#F1){ref-type="fig"}).

###### 

Patient and tumour characteristics.

  Characteristic                                         Patients   
  ------------------------------------------------------ ---------- ----
                                                         N          \%
  **Age**                                                43-77      
  Mean                                                   62         
  Range                                                             
  **Sex**                                                           
  Male                                                   16         80
  Female                                                 4          20
  **ECOG Status**                                                   
  0                                                      16         80
  1                                                      4          20
  **Smoking Status**                                                
  No                                                     8          40
  \< 1 packet                                            7          35
  \>1 packet                                             5          25
  Alcohol Intake                                                    
  No                                                     9          45
  \< 1 litre/day                                         7          35
  \> 1 litre/day                                         4          20
  **HPV Status [^\*^](#T2FN1){ref-type="table-fn"}**                
  Negative                                               7          50
  Positive                                               2          14
  Unknown                                                5          36
  **Primary Site**                                                  
  Tonsil                                                 7          35
  Base of tongue                                         5          25
  Soft palate                                            2          10
  Nasopharynx                                            6          30
  **T Stage**                                                       
  1                                                      4          20
  2                                                      8          40
  3                                                      3          15
  4                                                      5          25
  **N Stage**                                                       
  0                                                      7          35
  1                                                      3          15
  2                                                      10         50
  **AJCC Stage [^\*\*^](#T2FN2){ref-type="table-fn"}**              
  II                                                     6          30
  III                                                    4          20
  IV                                                     10         50
  **Medical therapy**                                               
  None                                                   4          20
  Cisplatin                                              13         65
  Cetuximab                                              3          15
                                                                    

HPV status was assessed for patients with oropharynx cancer

AJCC Stage = American Joint Committee on Cancer

![Dose to the SWOARs.\
Abbreviations: SPCM: superior constrictor muscle; MPCM: middle constrictor muscle; IPCM inferior constrictor muscle; SL supraglottic larynx; GL glottic larynx; CMP cricopharyngeal muscle; EC cervical esophagus; Dm = mean dose](0392-100X-36-174-g001){#F1}

All patients but one, who stopped chemotherapy after two administrations due to a high grade long-term nausea and vomit, received at least five of the planned six cycles of concurrent medical therapy. No patient experienced a significant weight loss (≥ grade 2) requiring PEG positioning during or soon after treatment.

Mucositis G1 was reported in 7 patients (35%) and was G2 in 11 patients (55%) and G3 in 2 patients (10%). Eight patients reported G1 dysphagia (40%), 10 patients G2 (50%) and 2 patients G3 (10%), whereas 10 patients reported G1 xerostomia (50%) and 10 patients G2 xerostomia (50%).

Moreover, 4 patients (20%) referred no pain during the course of treatment, whereas 7 patients referred G1 (35%), 8 patients G2 (40%) and 1 patient G3 (5%).

Variations of swallowing parameters between baseline and 1 month after RT {#S3a}
-------------------------------------------------------------------------

The examination of the differences between the pre- and post-treatment HPRI score was found to be statistically significant both at FEES-L (p = 0.021) and SL (p = 0.02) and at VFS-L (p = 0.008) and SL (p = 0.005); OPES did not confirm these results ([Table III](#T3){ref-type="table"}).

###### 

Comparison between pre- and post-treatment HPRI for the three different exams used.

  Parameter                                                                                                           Exam                                      Median (range)   p-value   
  ------------------------------------------------------------------------------------------------------------------- ----------------------------------------- ---------------- --------- -------
  HPRI[^a^](#T3FN1){ref-type="table-fn"} 0-1[^b^](#T3FN2){ref-type="table-fn"} L [^c^](#T3FN3){ref-type="table-fn"}   FEES [^e^](#T3FN5){ref-type="table-fn"}   0 (0-1)          1 (0-2)   0.021
                                                                                                                      VFS [^f^](#T3FN6){ref-type="table-fn"}    1 (0-3)          2 (0-3)   0.008
                                                                                                                      OPES [^g^](#T3FN7){ref-type="table-fn"}   1(0-2)           1 (0-1)   0.480
  HPRI 0-1 SL [^d^](#T3FN4){ref-type="table-fn"}                                                                      FEES                                      0 (0-2)          1 (0-2)   0.020
                                                                                                                      VFS                                       1 (0-3)          3 (1-3)   0.005
                                                                                                                      OPES                                      1(0-2)           1 (1-2)   0.058

HPRI= Hypopharyngeal Retention Index;

0-1= parameter worsening score between baseline and 1 month after treatment;

L=liquid;

SL=semiliquid;

FEES= Fibreoptic endoscopic evaluation of swallowing;

VFS=Videofluoroscopy;

OPES=Oropharyngeal oesophageal scintigraphy

HPRI worsening scores from baseline to 1 month after treatment are shown in [Tables IV](#T4){ref-type="table"} and [V](#T5){ref-type="table"}.

###### 

HPRI scores after L bolus by the three different exams used.

  Time         Parameter   Exam   Total   Score   Score Index                                          
  ------------ ----------- ------ ------- ------- ------------- ---- ---- ---- ---- ---- ------ ------ ------
  Pretherapy   HPRI        FEES   20      17      85            3    15   0    0    0    0      0.16   0.37
  1 month      HPRI        20     9       45      9             45   2    10   0    0    0.65   0.67   
  Pretherapy   HPRI        VFS    20      6       30            5    25   4    20   5    25     1.47   1.17
  1 month      HPRI        20     1       5       4             20   6    30   9    45   2.21   0.92   
  Pretherapy   HPRI        OPES   20      8       40            11   55   1    5    0    0      0.68   0.58
  1 month      HPRI        20     8       40      12            60   0    0    0    0    0.60   0.50   

Abbreviations FEES=Fiberoptic endoscopic swallowing evaluation; VFS=Videofluoroscopy; OPES=Oro-pharyngeal-oesophageal scintigraphy; HPRI=Hypopharyngeal retention Index; SD=Standard deviation

###### 

HPRI scores after SL bolus at the three different exams used.

  Time         Parameter   Exam   Total   Score   Score Index                                          
  ------------ ----------- ------ ------- ------- ------------- ---- ---- ---- ---- ---- ------ ------ ------
  Pretherapy   HPRI        FEES   20      16      80            3    15   1    5    0    0      0.28   0.57
  1 month      HPRI        20     6       30      14            70   0    0    0    0    0.70   0.47   
  Pretherapy   HPRI        VFS    20      6       30            5    25   4    20   5    5      1.47   1.17
  1 month      HPRI        20     0       0       3             16   6    32   9    10   2.37   0.76   
  Pretherapy   HPRI        OPES   20      5       25            10   50   5    25   0    0      1.05   0.70
  1 month      HPRI        20     0       0       12            60   8    40   0    0    1.40   0.50   

Abbreviations FEES = Fiberoptic endoscopic swallowing evaluation; VFS = Videofluoroscopy; HPRI = Hypopharyngeal retention index; SD = Standard deviation

A total of 11 (55%), 19 (95%) and 12 (60%) patients experienced poorer scores at FEES-L, VFS-L and OPES-L.

All patients showed a poorer HPRI score at VFS-SL and OPES-SL, as well as 14 (70%) at FEES-SL. In this regard, 9 (45%) and 10 (50%) patients showed a severe HPRI score (grade 3) after treatment at VF-L and SL, respectively. Furthermore, the relationship between HPRI worsening at FEES-L and FEES-SL (p = 0.005) as well as at VFS-L and VFS-SL (p \< 0.001), was statistically significant ([Figs. 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}). On the contrary, PTT and WPO was not significantly affected by RT either after L or SL bolus intake, as shown in [Table VI](#T6){ref-type="table"}.

###### 

Comparison between pre and post-treatment PTT for the three different exams.

  Parameter                                                                                                          Exam                                      Median (range)   p-value   
  ------------------------------------------------------------------------------------------------------------------ ----------------------------------------- ---------------- --------- -------
  WOP[^a^](#T6FN1){ref-type="table-fn"} 0-1 L                                                                        FEES [^f^](#T6FN6){ref-type="table-fn"}   0 (0-1)          0 (0-1)   0.219
  PTT[^b^](#T6FN2){ref-type="table-fn"} 0-1[^c^](#T6FN3){ref-type="table-fn"} L [^d^](#T6FN4){ref-type="table-fn"}   VFS [^g^](#T6FN7){ref-type="table-fn"}    0 (0-3)          0 (0-0)   1.0
  PTT 0-1 L                                                                                                          OPES [^h^](#T6FN8){ref-type="table-fn"}   0 (0-0)          0 (0-1)   1.0
  WOP 0-1 SL                                                                                                         FEES                                      0 (0-1)          0 (0-2)   0.454
  PTT 0-1 SL [^e^](#T6FN5){ref-type="table-fn"}                                                                      VFS                                       0 (0-1)          0 (0-0)   0.756
  PTT 0-1 SL                                                                                                         OPES                                      0 (0-0)          0 (0-0)   1.0

WOP = White-out phase;

PTT = Pharyngeal transit time;

0-1 = parameter worsening score between baseline and 1 month after treatment;

L = Liquid;

SL = Semiliquid;

FEES = Fibreoptic endoscopic evaluation of swallowing;

VFS = Videofluoroscopy;

OPES = Oro-pharyngeal-oesophageal scintigraphy.

![Relationship between HPRI worsening score at FEES-L and SL.\
Abbreviations: 0-1 = parameter worsening score between baseline and 1 month post-treatment. L = Liquid; SL = Semiliquid; HPRI = hypopharyngeal retention index; FEES = Fibreoptic endoscopic evaluation of swallowing.](0392-100X-36-174-g002){#F2}

![Relationship between VFS worsening score at VFS-L and SL.\
Abbreviations: 0-1 = parameter worsening score between baseline and 1 month post-treatment. L = Liquid; SL = Semiliquid; HPRI = Hypopharyngeal retention index; VFS=Videofluoroscopy.](0392-100X-36-174-g003){#F3}

Six patients (2 nasopharynx, 1 base of tongue, 1 tonsil and 1 soft palate) showed a worsening of the PTT score resulting in a mild prolongation time (grade 1) at FEES-L and only 1 patient (tonsil) at OPES-L. A mild (grade 1) PTT prolongation was observed in 4 patients (1 tonsil, 1 base of tongue, 1 nasopharynx and 1 soft palate) and 3 patients (1 base of tongue, 1 nasopharynx and 1 soft palate) at FEES-SL and VFS-SL, respectively. Moreover, one patient (tonsil) experienced a moderate (grade 2) PTT prolongation at FEES-SL. No case of PTT prolongation time at 1 month after RT was seen at VFS-L and at OPES-SL.

Finally, analysis of the development of pre-deglutition penetration and aspiration was limited owing to the restricted number of patients with pre-swallowing penetration (only 1 patient at FEES-L and 1 patient at FEES-SL) and aspiration (only 1 patient at OPES-L and 1 patient at FEES-SL) after RT, which did not reach statistical significance.

Specifically, pre-deglutition penetration at 1 month was detected in only 1 patient (base of tongue) at FEES-L and SL and aspiration at 1 month was detected in only 1 patient (nasopharynx) by OPES-L and FEES-SL, respectively.

Baseline dysphagia assessment and tumour characteristics {#S3b}
--------------------------------------------------------

Association between primary site (nasopharynx vs oropharynx), T stage (T1-2 vs. T3-T4), N stage (N0 vs N1-2) and baseline dysphagia parameters using the three different exams was assessed after L and SL bolus intake. No significant association was found between primary site, T and N stage with the baseline HPRI (p \> 0.405) or PTT (p \> 0.314).

Moreover, analysis of the association with baseline pre-deglutition penetration and aspiration showed a limited number of patients with baseline pre-deglutition penetration and/or aspiration, which did not reach statistical significance.

In more detail, baseline HPRI was altered in 14 patients (70%) at VFS-L and SL and in 13 patients (65%) and 15 patients (75%) at OPES-L and SL, respectively.

These data were not confirmed at FEES-L and SL, as shown in [Table VII](#T7){ref-type="table"}.

###### 

Baseline HPRI scores with the three different exams.

  HPRI                                                                                                            Grade 0   \%   Grade 1   \%   Grade 2   \%   Grade 3   \%
  --------------------------------------------------------------------------------------------------------------- --------- ---- --------- ---- --------- ---- --------- ----
  FEES[^a^](#T7FN1){ref-type="table-fn"} 0[^d^](#T7FN4){ref-type="table-fn"}L[^e^](#T7FN5){ref-type="table-fn"}   17        85   3         15   \-        \-   \-        \-
  VFS[^b^](#T7FN2){ref-type="table-fn"} 0L                                                                        6         30   5         25   4         20   5         25
  OPES[^c^](#T7FN3){ref-type="table-fn"} 0L                                                                       7         35   12        60   1         5    \-        \-
  FEES 0SL[^f^](#T7FN6){ref-type="table-fn"}                                                                      16        80   3         15   1         5    \-        \-
  VFS 0SL                                                                                                         6         30   5         25   4         20   5         25
  OPES 0SL                                                                                                        5         25   10        30   5         25   \-        \-

FEES = Fiberoptic endoscopic swallowing evaluation;

VFS = Videofluoroscopy;

OPES = Oro-pharyngeal-oesophageal scintigraphy;

0 = Baseline evaluation;

L = Liquid;

SL = Semiliquid.

In this regard, 3 patients (1 tonsil, 1 base of tongue and 1 nasopharynx) showed a mild HPRI at FEES-L and SL, and 1 patient (tonsil) showed a moderate HPRI at FEESSL. In contrast, baseline PTT after L bolus intake was normal in all patients but one (tonsil cancer), in whom mild prolongation (grade 1) was seen at FEES.

Furthermore, moderate PTT prolongation (grade 2) was observed in 3 patients at FEES-SL (2 with tonsil and 1 with base of tongue cancer) and in 2 patients at VFS-SL (tonsil cancer). The PTT was normal in all patients at OPES-SL. Baseline pre-deglutition penetration was detected in only 1 patient (nasopharynx cancer) at FEES-L, VFS-L and OPES-L, in 3 patients at FEES-SL (2 with nasopharynx cancer and 1 with tonsil cancer) and in only 1 patient (nasopharynx cancer) at VFS-SL and OPES-SL. Finally, aspiration was observed in only 2 patients (10%) affected by tonsil and base of tongue cancer, respectively, at OPES-L.

Discussion {#S4}
==========

The results of our study showed that post-deglutition HPRI was the most sensitive parameter, independently of the exam and consistency of the bolus.

Our data showed a significant number of patients who experienced an increased HPRI score from baseline to 1 month after RT, especially using VFS and FEES rather than OPES. This difference is probably due to the poor anatomical resolution of OPES together with the difficulty for the nuclear physician to correctly create a region of interest (ROI ) with the subsequent risk to overestimate the pattern of dysphagia.

Our explanation is supported by the high percentage of patients with baseline increased HPRI score at OPES-L and SL (65% and 75%, respectively), which probably justifies the lack of statistical difference between pre- and post-RT. Hence, we believe that OPES should be considered as a complementary exam in assessment of radiationinduced dysphagia. Indeed, this is supported by a recent systematic review of oropharyngeal dysphagia assessment by Speyer et al. [@R25].

On the other hand, the significant worsening of HPRI score seen at FEES and VFS was probably related to inflammatory oedema of pharyngeal mucosa, constrictor muscles and base of tongue causing a reduction of tongue strength and motion, pharyngeal contraction and laryngohyoid elevation with a consequent increased number of swallows needed to clear the bolus [@R37].

Lazaurus et al., Wu et al., and Jensen et al. [@R38]^-^[@R40] have published similiar results, reporting a significant amount of pharyngeal retention (88-93.5%) and post-deglutition aspiration (59-77.4%) after RT alone for patients affected by different HN cancer sites. Similar results were reported by most studies on patients submitted to concomitant chemo-radiation protocols [@R41]^-^[@R44].

In our preliminary experience, a linear relationship was observed between HPRI worsening score after L and SL bolus using the same exam. This finding might be explained by a similar muscular effort in the deglutition act for the two different consistencies of bolus. As reported by most literature data, the instrumental assessment of dysphagia is based on deglutition evaluation after L and SL bolus intake [@R45] [@R46]. Likewise, most patients undergoing radio- or radiochemotherapy for HN cancer favour a soft diet owing to acute radiation-induced mucositis and xerostomia [@R47].

Thus, dysphagia assessment using solid bolus might have shown a higher percentage of HPRI worsening due to the requirement of a stronger muscular propulsion in this set of patients.

On the contrary, PTT changes from baseline to 1 month after RT were not statistically significant. Among the four deglutition parameters, PTT is the most difficult to disclose regardless of the type of exam. In our experience, no case of severe PTT prolongation was observed either at baseline or 1 month after RT. In addition, only a few patients experienced mild or moderate PTT prolongation after L (30% at FEES and 5% at OPES, respectively) and SL bolus intake (25% at FEES and 15% at VFS, respectively). This result is probably related to the low specificity of the three exams in revealing such a subtle parameter, causing a significant percentage of false negative patients and lack of variations from before to after treatment.

Our clinical study was aimed to prospectively evaluate the impact of RT using IMRT on deglutition function through complementary instrumental assessment.

This issue has been addressed by only few studies [@R10] [@R16] [@R17] [@R19], mostly reporting retrospective clinical results on patients affected by tumours arising from different HN sites, which limited the validity of the final data.

According to the recent recommendations by the Italian Association of Radiation Oncology, objective instrumental evaluation was performed using FEES, VFS and OPES before and after RT [@R48]. Selection criteria were defined to properly assess the impact of RT in a homogeneous subset of HN cancer patients to maximally avoid selection bias.

Firstly, we excluded the patients affected by oral, larynx and hypopharynx cancer due to the high prevalence of baseline cancer-related dysphagia [@R49] as well as those who underwent previous surgery and/or RT in HN region or with deglutition-related comorbidities (i.e. neurological or rheumatological diseases).

Moreover, patients with Stage IVB (T4b or N3) or C (M1) disease were not enrolled mainly due to the poor prognosis that significantly reduces the importance of deglutition evaluation.

Aiming to strictly assess the radiation-induced dysphagia, patients who previously underwent neoadjuvant chemotherapy were excluded due to the significant percentage of chemotherapy-related dysphagia (20-40%) that could worsen deglutition function before the beginning of standard radio- or radiochemotherapy [@R50].

In fact, the lack of significant correlation between pretreatment dysphagia parameters and tumour characteristics (primary site, T and N Stage) demonstrates the validity of our selection criteria.

Furthermore, our study investigated both acute (1 month) and late (6 and 12 months) radiation-induced dysphagia.

In this paper, we report the results of acute dysphagia (at 1 month after RT). Our preliminary findings showed that IMRT aimed to SWOARs-sparing caused an increase of postswallowing HPRI, but did not significantly influence the occurrence of pre-deglutition penetration and aspiration.

In this regard, we believe that the post-treatment increase of HPRI may also be related to mucositis and xerostomia, which occurs during the course of RT, with a consequent increased difficulty to the transit of bolus through the pharyngeal region [@R51]^-^[@R53].

Therefore, the radiation oncologist must pay attention to maximally reduce the dose delivered to the major salivary glands and pharyngeal uninvolved mucosa rather than to the SWOARs.

In contrast, the use of IMRT aimed to spare SWOARs irradiation, probably contributed to the low incidence (only 1 patient) of post-deglutition penetration and aspiration.

In this regard, Feng et al. [@R54] initially and Eisbruch et al. ([@R55]) afterwards, reported the data of the only prospective study by the University of Michigan on 73 oropharyngeal cancer patients undergoing IMRT and evaluated at 3, 12 and 24 months using both clinical (CTCAE scale) and instrumental (videofluoroscopy) assessment criteria. The authors reported a slight worsening of VFS scores (mild to moderate dysphagia) from pre-therapy to soon after therapy (3 months) that did not improve at subsequent follow-up (12 and 24 months).

Conclusions {#S5}
===========

At present, our early preliminary data seem to confirm the experience reporting no cases of severe side effects (PEG positioning or clinical aspiration) as well as a low percentage of major instrumental dysfunction (pre-deglutition penetration or aspiration). In our opinion, IMRT significantly limits severe acute deglutition sequelae in HN cancer patients compared with historical literature data ^(^[@R56]^,^[@R57]^)^. Indeed, longer follow-up and larger sample size are needed to further evaluate if the observed increase of hypopharyngeal retention of food is subsequently related to a high risk of developing late aspiration (6 and 12 months).
